The Use of Urinary Nuclear Matrix Protein 22 (NMP22) as a Diagnostic Adjunct to Urine Cytology for Monitoring of Recurrent Bladder Cancer-Institutional Experience and Review

Onal B., Han U., Yilmaz S., Koybasioglu F., Altug U.

DIAGNOSTIC CYTOPATHOLOGY, vol.43, no.4, pp.307-314, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 43 Issue: 4
  • Publication Date: 2015
  • Doi Number: 10.1002/dc.23239
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.307-314
  • Keywords: NMP22, urine cytology, urothelial carcinoma bladder, recurrence, performance, TRANSITIONAL-CELL CARCINOMA, TUMOR-MARKERS, RISK, NUCLEAR-MATRIX-PROTEIN-22, SURVEILLANCE, NMP-22
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes


BackgroundThis prospective study compares urine NMP22 immunoassay and cytomorphology for detecting recurrent urothelial carcinoma (UC) of the bladder and correlates between NMP22 levels and grade, multiplicity, and size of the tumor. We aimed refining the use of NMP22 test in the management of UC at our institution.